Jasper Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Jasper Therapeutics
JSPRW Stock  USD 0.02  0  10.53%   
Jasper Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Jasper Therapeutics' valuation are provided below:
Earnings Share
(3.84)
There are over one hundred seventeen available fundamental trends for Jasper Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should confirm Jasper Therapeutics' regular fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable.
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 13.1 M or Other Operating Expenses of 47.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.78. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Jasper Stock
Check out the analysis of Jasper Therapeutics Correlation against competitors.
For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Jasper Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets67.4 M91.9 M45.4 M
Slightly volatile
Other Current Liabilities12.2 M11.6 M3.9 M
Slightly volatile
Total Current Liabilities8.9 M17.5 M5.5 M
Slightly volatile
Net Tangible Assets73 M75.9 M91.3 M
Slightly volatile
Warrants69 M71.4 M86.4 M
Slightly volatile
Accounts Payable2.9 M4.6 M1.7 M
Slightly volatile
Cash60.2 M82.4 M42.1 M
Slightly volatile
Non Current Assets Total4.6 M4.7 M2.1 M
Slightly volatile
Non Currrent Assets Other920.3 K943 K430.3 K
Slightly volatile
Cash And Short Term Investments60.2 M82.4 M42.1 M
Slightly volatile
Common Stock Total Equity447524401
Slightly volatile
Common Stock Shares Outstanding17.6 M16.8 M3.9 M
Slightly volatile
Short Term Investments80.1 M90.1 M98.4 M
Slightly volatile
Liabilities And Stockholders Equity67.4 M91.9 M45.4 M
Slightly volatile
Non Current Liabilities Total2.6 M2.7 M7.6 M
Pretty Stable
Capital Surpluse9.4 M13.9 M7.9 M
Slightly volatile
Other Stockholder Equity365.3 M347.9 M91 M
Slightly volatile
Total Liabilities18.1 M16.4 M13.3 M
Slightly volatile
Long Term Investments110.3 M115.4 M101.7 M
Slightly volatile
Total Current Assets62.7 M87.2 M43.3 M
Slightly volatile
Non Current Liabilities Other1.9 M2 M2.9 M
Slightly volatile
Common Stock2.9 K1.8 K6.9 K
Slightly volatile
Short and Long Term Debt Total2.8 M2.1 M2 M
Slightly volatile
Property Plant And Equipment Net4.3 M3.3 M2.8 M
Slightly volatile
Long Term Debt10.5 M11.8 M12.9 M
Slightly volatile
Net Receivables213.8 K225 K552.7 K
Slightly volatile
Long Term Debt Total10.5 M11.8 M12.9 M
Slightly volatile
Capital Lease Obligations2.8 M2.1 M2 M
Slightly volatile
Property Plant And Equipment Gross5.6 M7.7 M3.5 M
Slightly volatile
Capital Stock1.9 K1.8 K1.5 K
Slightly volatile
Net Working Capital59 M69.7 M33.2 M
Slightly volatile
Current Deferred Revenue2.2 M2.5 M2.8 M
Slightly volatile
Short Term Debt943.5 K1.3 M657.8 K
Slightly volatile

Jasper Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.2 M1.2 M4.4 M
Pretty Stable
Selling General Administrative13.1 M23.5 M6.9 M
Slightly volatile
Other Operating Expenses47.4 M87.7 M25.6 M
Slightly volatile
Research Development34.3 M64.2 M18.7 M
Slightly volatile
Total Operating Expenses47.4 M87.7 M25.6 M
Slightly volatile
Cost Of Revenue963.2 K1.6 M419.4 K
Slightly volatile
Net Interest Income4 M5.8 M1.7 M
Slightly volatile
Interest Income4 M5.8 M1.7 M
Slightly volatile
Selling And Marketing Expenses886.4 K997.2 K1.1 M
Slightly volatile

Jasper Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8 M7.6 M2 M
Slightly volatile
Begin Period Cash Flow105.4 M100.4 M27.3 M
Slightly volatile
Total Cash From Financing Activities53.2 M55.1 M38.9 M
Slightly volatile
End Period Cash Flow60.5 M82.9 M42.2 M
Slightly volatile
Depreciation921.6 K1.6 M405.9 K
Slightly volatile
Issuance Of Capital Stock59.9 M54.3 M29.3 M
Slightly volatile
Other Cashflows From Investing Activities17.1 K18 K135.1 K
Slightly volatile
Change To Netincome4.7 M5.3 M5.8 M
Slightly volatile
Change To Liabilities126.5 K142.3 K155.3 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.440.464.6627
Slightly volatile
Cash Per Share5.375.65104
Slightly volatile
Income Quality0.660.790.5869
Slightly volatile
Net Debt To EBITDA1.411.071.8985
Slightly volatile
Current Ratio8.775.7210.8799
Slightly volatile
Capex Per Share0.04140.04351.5227
Slightly volatile
Interest Debt Per Share0.140.12436.3568
Slightly volatile
Debt To Assets0.05020.02610.0588
Slightly volatile
Price Earnings To Growth Ratio0.20.190.0617
Slightly volatile
Ebt Per Ebit1.11.081.0434
Pretty Stable
Quick Ratio8.775.7210.8799
Slightly volatile
Cash Ratio8.485.4110.7544
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.161.0689
Very volatile
Debt Ratio0.05020.02610.0588
Slightly volatile

Jasper Fundamental Market Drivers

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.5 M2.2 M
Cost Of Revenue1.6 M963.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GMGeneral Motors
GMGeneral Motors
CCitigroup

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY